Carfilzomib for the Prevention of Graft Versus Host Disease

Inclusion Criteria: 1. Patients with MDS/AML 2. 18 years or older and willing and able to comply with the protocol requirements. 3. LVEF ≥ 40%. 2-D transthoracic echocardiogram (ECHO) is the preferred method of evaluation. Multigated Acquisition Scan (MUGA) is acceptable if ECHO is not available. 4. Patients undergoing 8-10/10 HLA matched unrelated and unmanipulated PBSC transplantation 5. Patients conditioned with reduced intensity or reduced toxicity conditioning i.e. Fludarabine combine with Treosulfan or 2-4 days of I.V Busulfan. 6. Patients must sign written informed consent. 7. Adequate birth control in fertile patients. Exclusion Criteria: 1. Patients undergoing other type of transplantation or with other type of basic disease other than AML or MDS. 2. Patients with respiratory failure (DLCO \< 30%). 3. Active congestive heart failure (New York Heart Association \[NYHA\] Class III to IV), symptomatic ischemia, or conduction abnormalities uncontrolled by conventional intervention. 4. Patients with \> grade II liver renal toxicity. 5. Psychiatric conditions/disease that impair the ability to give informed consent or to adequately co-operate 6. Bilirubin \> 3.0 mg/dl, transaminases \> 3 times upper normal limit 7. Creatinine \> 2.0 mg/dl 8. ECOG-Performance status \> 2 9. Uncontrolled infection 10. Pregnancy or lactation 11. CNS disease involvement 12. Pleural effusion or ascites \> 1 liter.